Find a study
Browse recruiting studies near you — free to check, always your choice.
59 studies
Recruiting now, in plain language. Every study is watched over by an independent ethics board.
- DepressionAnxiety
Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
Testing whether therapy sessions can help teens and young adults with sickle cell cope with
📍 Children's Hospital Los Angeles · Los Angeles, CA · Get directions →
The current study seeks to build on previous research that demonstrates the efficacy of Acceptance and Commitment Therapy in combating stigma by investigating the feasibility and acceptability of a protocol to support Black adolescents and young adults in coping with race related stress. The study will consist of a small, purposeful, non-randomized sample (N = 30) of clients enrolled into a 10-session Acceptance and Commitment Therapy group.
- Asthma
The Safety, Feasibility, and Repeatability of Inhaled ATP Cough Challenges
Testing whether inhaling ATP to trigger cough is safe and repeatable in people with asthma
📍 Respiratory Research Lab · Hamilton, Ontario · Get directions →
The inhalation of adenosine 5'-triphosphate (ATP) to evoke cough (ATP cough challenge) is becoming increasingly used as a tool to measure cough hypersensitivity in patients with chronic cough. However, the safety, feasibility, and repeatability of this procedure is not widely known.
- Depression
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
Testing whether a brain receptor change affects ketamine’s effect on depression
📍 Yale University · New Haven, CT · Get directions →
The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
- Fatty liver disease (NASH/MASH)
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
Testing an experimental medicine for MASLD or MASH in adults
📍 Arizona Liver Health · Chandler, AZ · +1 more US site · Get directions →
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B).
- Fatty liver disease (NASH/MASH)
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
Testing a new medicine for liver disease in adults with extra body fat
📍 Altasciences Clinical Company, Inc · Montreal, Quebec · Get directions →
The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat. Participants will receive either NNC4005-0001, which is the treatment being tested, or a placebo, which is a treatment that contains no active medicine.
- Depression
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans
Testing how dimethyltryptamine affects safety and depression symptoms
📍 Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine, · West Haven, CT · Get directions →
The goal of this phase 1 study is to investigate the safety and efficacy of dimethyltryptamine (DMT) in individuals with depression and healthy controls. We hypothesize that administration of DMT will result in decreases in depression, associated symptoms, and neuroplastic changes in depressed subjects.
- Depression
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
Testing whether a low-dose ketamine IV treatment is safe and workable in the ER for people with
📍 University of Kansas Strawberry Hill Campus · Kansas City, KS · +1 more US site · Get directions →
There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.
- Depression
Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression
Testing how one-time exercise and ibuprofen affect bipolar depression symptoms
📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →
This is a 2x2, within-subjects, cross-over trial to test the anti-depressant effects of acute exercise in 20 participants with bipolar depression. Participants will complete four experimental sessions, two with an exercise challenge and two with a resting control condition in a counterbalanced order.
- DepressionAnxiety
ACT for Individuals With MNCD and Their Care Partners
Testing acceptance commitment therapy for depression and anxiety in dementia
📍 Texas Tech University Plaza Building · Lubbock, TX · Get directions →
This project aims to implement and evaluate a dyadic intervention (i.e., acceptance commitment therapy) for persons with AD/ADRD and their care partners. We hypothesize the intervention will be feasible, acceptable, and show preliminary efficacy of the dyadic interveniotns.
- Type 2 diabetesFatty liver disease (NASH/MASH)
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
Testing QX1206 in people with type 2 diabetes and fatty liver
📍 Centricity Research Toronto LMC. · Toronto, · Get directions →
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose.
- Depression
RCT of Psilocybin-assisted CBT for Depression
Testing psilocybin with cognitive-behavioral therapy for depression
📍 UCLA Semel Institute · Los Angeles, CA · Get directions →
The primary objectives of this clinical investigation are to (1) determine the acceptability and feasibility of joining psilocybin-assisted therapy with cognitive-behavioral therapy (PA-CBT) for patients with depression, (2) optimize CBT to most effectively integrate the psilocybin experience with psychotherapy and (3) examine the clinical benefit of psilocybin as an adjunct to cognitive-behavioral therapy (CBT) for major depressive disorder. This study is a randomized, two-arm, fixed dose trial that will test the feasibility, acceptability, and participant and therapist adherence to PA-CBT.
- Asthma
A Study of CDX-622 in Participants With Mild to Moderate Asthma
Testing the safety and how a medicine affects the body in adults with mild to moderate asthma
📍 University of California, San Francisco · San Francisco, CA · +3 more US sites · Get directions →
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
- Depression
Psilocybin for Treatment-Resistant Depression in Autism
Testing psilocybin plus talk therapy for depression in autistic adults
📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →
We propose a first-of-its-kind open-label clinical trial to investigate the feasibility, tolerability, and safety of administering psilocybin in autistic adults with treatment-resistant depression (TRD). In this study, 20 participants (intellectually able and fluent-speech adults) with autism and co-occurring TRD will receive around 20 hours of manualized psychotherapy that has previously been used with psilocybin (Agin-Liebes et al., 2020).
- Asthma
A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma
Testing how different doses of a new medicine affect safety and the body in people with mild to
📍 Pfizer Clinical Research Unit - New Haven · New Haven, CT · Get directions →
The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma. This is the first time the study medicine is being given to people.
- Depression
Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine
Testing how ketamine changes brain chemicals in people with depression
📍 University of Pennsylvania · Philadelphia, PA · Get directions →
In the treatment of Major Depressive Disorder (MDD), ketamine can produce rapid but short-lasting improvements in mood. In order to develop a new generation of treatments with rapid and sustained efficacy, a better understanding of the mechanism of action is urgently needed.
- DepressionAnxiety
Integrating Inuit Knowledge Principles in Multi-Level Mental Health Clinical Trials
Testing whether eating more country foods and cultural activities help Inuit adults with depression
📍 Aqqiumavvik Society · Arviat, Nunavut · Get directions →
This study is looking at how eating more country foods affects mental health among Inuit men and women in Arviat, NU. The goal is to evaluate if eating more of these foods helps people feel less depressed or anxious, and whether being part of food-gathering and cultural activities also makes a difference.
- Depression
DBS for Depression
Testing whether deep brain stimulation is safe and feasible for severe depression that hasn’t
📍 Zucker Hillside Hospital · Queens, NY · Get directions →
The goal of this clinical trial is to demonstrate the feasibility and safety of deep brain stimulation in treatment resistant depression. The main questions it aims to answer are: * Is deep brain stimulation effective in treating treatment resistant depression?
- Asthma
Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation
Testing early IV magnesium sulfate for people with a moderate asthma flare
📍 Oklahoma Children's Hospital · Oklahoma City, OK · Get directions →
This study aims to identify whether early administration of magnesium sulfate in moderate asthma exacerbations can potentially avoid admission, decrease length of stay in the emergency department (ED), decrease length of stay (LOS) in the general hospital floor vs pediatric intensive care unit (PICU), and decrease the need for respiratory support.
- Depression
Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression
Testing whether donor stem cells are safe and helpful for hard-to-treat bipolar depression
📍 The University of Texas Health Science Center at Houston · Houston, TX · Get directions →
The overall objective of the investigators is to assess the therapeutic efficacy and tolerability of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) isolated from hematogenous bone marrow for treatment of treatment-resistant bipolar depression patient (TRBD).
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Human Models of Selective Insulin Resistance: Alpelisib, Part I
Testing how insulin works in healthy people versus people at risk for type 2 diabetes
📍 Columbia University Irving Medical Center · New York, NY · Get directions →
The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin.
- Depression
Pharmacologic Augmentation of TMS for Depression With D-serine
Testing whether adding D-serine to TMS sessions helps depression
📍 McLean Hospital · Belmont, MA · Get directions →
The goal of this study is to test whether combining D-serine with 30 treatments of a) iTBS and b) 18-Hz protocols will enhance clinical outcomes compared to rTMS with placebo (i.e., sugar pill). The investigators hypothesize that NMDA receptor activation via D-serine combined with repeated sessions of rTMS will produce greater clinical outcomes than iTBS with placebo and 18-Hz with placebo.
- Depression
Neural Response to Inflammatory Challenge in Major Depressive Disorder
Testing brain and immune responses to an inflammation trigger in depression
📍 Laureate Institute for Brain Research · Tulsa, OK · Get directions →
This is a parallel group, double-blinded, placebo-controlled study. Participants with MDD (n=90) and HC (n=90) will be randomly assigned (2:1) to receive either lipopolysaccharide (LPS) (0.8ng/kg of body weight) or placebo (same volume of 0.9% saline) administered as an intravenous bolus.
- Depression
Probiotic Administration for Adolescent Depression
Testing whether a probiotic affects brain and gut in teens with depression
📍 UCSF · San Francisco, CA · Get directions →
This double-blind, placebo-controlled clinical trial will examine the effect of probiotic Visbiome on the brain and gut microbiome of individuals 15 to 24 years of age.
- DepressionAnxiety
Open-Label Psilocybin Study in Transdiagnostic Population
Testing psilocybin for safety and symptom changes in people with depression or anxiety
📍 Connecticut Mental Health Center - Yale School of Medicine · New Haven, CT · Get directions →
The primary objective of this study is to investigate the safety, feasibility, and tolerability of psilocybin treatment in individuals with functional impairment due to psychiatric symptoms. The secondary objective of this study is to determine whether individuals with functional impairments due to psychiatric symptoms will experience statistically significant symptom reduction and functional improvement from baseline symptom measurements (Visit 3) to 1-week (Visit 7), 4-weeks (Visit 8), and 6-weeks (Visit 9) post dosing.
- Depression
A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
Testing a brain stimulation treatment to help knee arthritis pain and depression
📍 UCLA Semel Institute - Neuropsychiatric Institute (NPI) · Los Angeles, CA · Get directions →
Osteoarthritis (OA) is a major public health problem, and involvement of the knee is especially disabling. Symptomatic knee OA has an incidence rate between 40 to 1,020 per 100,000 person years1 and is among the most common causes of disability worldwide.
- DepressionAnxiety
Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use
Testing a chatbot to support people using cannabis with anxiety or depression
📍 46 Centerra Parkway, Suite 300, Office #333S · Lebanon, NH · Get directions →
This study tests a chatbot called Therabot-CALM to help people who use cannabis with anxiety and/or low mood. Participants will do questionnaires, try the chatbot for 4 weeks, and join virtual interviews to give feedback on how usable and helpful it feels. The goal is to see if the chatbot is acceptable to users and can improve symptoms.
- Depression
Confirmatory Efficacy Trial of Attention Bias Modification for Depression
Testing two types of attention-bias training for adults with depression
📍 Institute for Mental Health Research · Austin, TX · Get directions →
The goal of this clinical trial is to compare the efficacy of two related, but different ABM (Attention Biased Modification) treatments for depression in adults with elevated symptoms of depression. The main aims are: * Aim 1:examine whether gamified ABM leads to greater change in the primary and secondary outcomes than sham ABM * Aim 1: establish that gamified ABM is at least as effective as traditional ABM.
- Depression
Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression
Testing how psilocybin affects the brain in people with hard-to-treat bipolar depression
📍 Toronto Western Hospital - University Health Network · Toronto, Ontario · Get directions →
This study is an open-label, single-arm, proof-of-concept study, wherein treatment resistant bipolar depression (TRBD) participants will receive one 25 mg dose of oral psilocybin accompanied by preparatory, monitoring, and integration psychotherapy sessions (psilocybin-assisted psychotherapy, or PAP). Using fMRI (functional magnetic resonance imaging), the findings of this study will provide data on the neurobiological mechanism of psilocybin in TRBD.
- Fatty liver disease (NASH/MASH)💵 May compensate
Evaluating the Pharmacokinetics and Safety of Miricorilant
Testing how a drug works in the body and its safety in adults with MASH
📍 Site# 433 · San Antonio, TX · Get directions →
A Phase 1b, Open-Label Study Evaluating the Pharmacokinetics and Safety of Miricorilant in Adult Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Fatty liver disease (NASH/MASH)
Bicalutamide Therapy in Young Women With NAFLD and PCOS
Testing bicalutamide in young women with fatty liver inflammation (NASH) and PCOS
📍 University of California San Francisco · San Francisco, CA · Get directions →
Nonalcoholic steatohepatitis (NASH), or fat-related liver inflammation and scarring is projected to be the leading cause of cirrhosis in the United States (U.S.) within the next few years. Women are at disproportionate risk for NASH, with approximately 15 million U.S.
- Depression
Theta-Burst Stimulation to Treat Depression
Testing a non-invasive brain stimulation approach to treat depression
📍 Centre for Addiction and Mental Health · Toronto, Ontario · Get directions →
The goal of this clinical trial is to explore the effects of non-invasive brain stimulation protocols using intermittent theta-burst stimulation (iTBS) on brain plasticity and depression severity in depressed individuals aged 18 to 50 years old. Brain plasticity is the brain's ability to change through growth or reorganization.
- Depression
Mood Effects of Serotonin Agonists: Depression
Testing how a low dose of LSD affects mood in people with depression
📍 University of Chicago · Chicago, IL · Get directions →
This study will examine the effect of a low dose of the 5HT2A agonist LSD (26 µg), compared to placebo, on acute and protracted mood states in individuals with depression. The investigators will assess the relationship between mood-related symptoms and EEG as a neurophysiological marker.
- Depression
Personalized Ultrasonic Brain Stimulation for Depression (R61)
Testing a personalized, noninvasive brain stimulation for depression
📍 University of Utah · Salt Lake City, UT · Get directions →
This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation parameters during psychological and physiological monitoring.
- Depression
A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression
Testing ketamine with group therapy for Spanish-speaking adults with depression
📍 Massachusetts General Hospital, Chelsea · Chelsea, MA · Get directions →
This is a pilot clinical trial to assess the feasibility, safety, and preliminary efficacy of ketamine-assisted group therapy for Spanish-speaking adults with depression
- Depression
Psilocybin in Chronic Low Back Pain and Depression
Testing psilocybin’s effects on chronic low back pain and depression
📍 Johns Hopkins University School of Medicine · Baltimore, MD · Get directions →
This study seeks to provide insight on psilocybin's effects on mechanisms of chronic pain among patients with co-morbid chronic low back pain and depression (CLBP+D). Participants will receive either a single high-dose of psilocybin (25mg absolute dose) or methylphenidate (40mg absolute dose).
- Depression
Pattern Separation in Major Depressive Disorder
Testing how depression treatments affect thinking, brain activity, and symptoms
📍 New York State Psychiatric Institute (NYSPI) · New York, NY · Get directions →
This study seeks to examine the effects of treatment with a selective serotonin reuptake inhibitor (SSRI), escitalopram, a first-line treatment for depression, in combination with placebo or with extended-release memantine, on neuropsychological function, regional brain activity assessed by functional magnetic resonance imaging, and depressive symptoms, in participants with Major Depressive Disorder. Escitalopram is administered in an open-label fashion in this study; extended release memantine is administered in a double-blind, randomized, placebo-controlled manner.
- Depression
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
Testing whether EEG gamma activity can predict 4-week ketamine treatment results for depression
📍 Wells Medicine · Houston, TX · +1 more US site · Get directions →
The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion.
- Asthma
Phase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma
Testing safety and how a single inhaled dose works in adults with asthma
📍 Sun City Clinical Research · Glendale, AZ · +1 more US site · Get directions →
This is a phase 1 study, randomized, double-blind, placebo-controlled, 2 treatment, 2 period crossover study to evaluate the pharmacokinetics, safety, and tolerability of a single inhaled dose of ASY202 in adults with stable asthma. Following screening, eligible participants will be enrolled and randomized to one of two treatment sequences.
- Depression
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
Testing how ketamine affects brain imaging and blood markers in depression
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: Most medications that treat depression take weeks or months to work. Researchers want to develop fast-acting treatments.
- Depression
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
Studying how ketamine may help depression work faster in people with treatment-resistant depression
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: Most drugs that treat mood disorders take a long time to work. Ketamine works within hours.
- DepressionAnxiety
Affect of Duavive on Mood & Anxiety Symptoms
Testing how Duavive affects mood and anxiety symptoms in early menopause women
📍 St Joseph's Healthcare · Hamilton, Ontario · Get directions →
This study evaluates the impact of conjugated estrogens/ bazedoxifene (CE/ BZA) on the mood (depression and anxiety) in peri- and early menopausal women.
- Depression
Effects of Low-intensity Transcranial Magnetic Stimulation on Major Depressive Disorder, and on 5-hydroxyindoleacetic Acid and Brain-derived Neurotrophic Factor Levels
Testing low-intensity TMS for depression and for blood brain markers
📍 High Specialty Medical Unit No. 1, Bajío. Mexican Social Security Institute · León, Guanajuato · Get directions →
The goal of this randomised clinical trial is to evaluate the effects of transcranial magnetic stimulation (TMS) on major depressive disorder (MDD) and on the levels of 5-hydroxyindoleacetic acid (5-HIAA) and brain-derived neurotrophic factor (BDNF). TMS works to treat MDD by using low-intensity magnetic fields to modulate certain areas of the brain, activating them which can help improve the mood of those suffering from the disorder.
- Depression
qEEG Brain Signature of Depression & Neuromodulation-induced Recovery
Testing how rTMS treatment for depression changes brain activity
📍 Sunnybrook Health Sciences Centre · North York, Ontario · Get directions →
This study aims to explore how repetitive transcranial magnetic stimulation (rTMS), a treatment for depression, affects brain function. Depression disrupts the brain's complex network or regions that regulate cognition, emotion, and behavior.
- Depression
Psilocybin to Treat Depression in Spinal Cord Injury
Testing whether psilocybin is safe for depression in people with spinal cord injury
📍 James J. Peters Department of Veterans Affairs Medical Center · The Bronx, NY · Get directions →
The main goal of this study is to determine if psilocybin is safe for use in people with SCI. The study will measure how people with SCI respond to three psilocybin doses: low (5mg), medium (10mg), and high (25mg).
- Depression
Synaptic Mechanisms of Continuous Theta Burst Stimulation in Depression
Studying how a repeated brain stimulation method may help depression
📍 McLean Hospital · Belmont, MA · Get directions →
Many people with depression do not get better with standard treatments like medication. One promising alternative is transcranial magnetic stimulation (TMS), a non-invasive procedure that uses magnetic pulses to stimulate specific brain regions.
- Fatty liver disease (NASH/MASH)
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Testing how a single dose affects drug levels and safety in adults with liver impairment and
📍 GSK Investigational Site · Rialto, CA · +2 more US sites · Get directions →
This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.
- Obesity / overweightFatty liver disease (NASH/MASH)💵 May compensate
Effect of Insulin Lowering on Lipogenesis
Testing whether lowering insulin for one week changes liver fat in people with obesity and MASLD
📍 Columbia University Irving Medical Center · New York, NY · Get directions →
The goal of this clinical trial is to compare a one-week course of diazoxide (2 mg/kg per dose x 14 doses) and placebo in people with obesity and insulin resistance (IR) with metabolic dysfunction-associated steatotic liver disease (MASLD). The main question it aims to answer are how mitigation of compensatory hyperinsulinemia with diazoxide affects hepatic de novo lipogenesis, a major contributor to MASLD pathophysiology.
- Asthma
Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation
Studying what body signals and immune cells drive asthma-related airway inflammation
📍 Massachusetts General Hospital · Boston, MA · Get directions →
Asthma is a heterogeneous disorder in which multiple potential inflammatory pathways contribute to airway obstruction. The biological basis for airway inflammation is the subject of intensive investigation.
- Depression
NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
Testing a drug approach for treatment-resistant depression by targeting brain circuits
📍 Washington University School of Medicine · St Louis, MO · Get directions →
Most clinical major depression responds to standard treatments (medication and psychotherapy); however, a significant subset of depressed patients (15-20%) do not respond to these treatments and are referred to as treatment-resistant major depression (TRMD). New treatments for TRMD are needed, and one promising line of research are drugs known as N-methyl-D-aspartate (NMDA) glutamate receptor antagonists.
- DepressionDementia / Alzheimer's
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
Testing psilocybin to treat depression in people with early Alzheimer’s or mild cognitive decline
📍 Johns Hopkins Center for Psychedelic and Consciousness Research · Baltimore, MD · Get directions →
This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.
- Depression
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
Testing brain imaging for an inflammation-related enzyme in depression
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: Researchers developed \[11C\]MC1, a radioligand for cyclooxygenase-2 (COX-2). COX-2 is an enzyme induced in the brain during inflammation.
- High blood pressureCOPD (chronic lung disease)Asthma
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
Testing a lung scan method using hyperpolarized oxygen gas MRI in healthy and people with COPD or
📍 University of Kansas Medical Center · Kansas City, KS · Get directions →
The purpose of this study is to develop and evaluate the usefulness of hyperpolarized (HP) 129Xe gas MRI for regional assessment of pulmonary function.
- DepressionAnxiety
PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)
Testing daily low-dose psilocybin to treat anxiety and depression in advanced illness patients
📍 The Ottawa Hospital · Ottawa, Ontario · Get directions →
The goal of this multi-centre phase I/II open-label, single-arm study is to determine the safety, feasibility, therapeutic dose, and preliminary efficacy of psilocybin microdosing to treat psychological distress among patients with advanced illness. Forty patients will receive psilocybin drug product (1-3mg per day, Mon-Fri) for 4 weeks to be administered via oral capsules by the participant.
- COPD (chronic lung disease)Asthma
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Pulmonary Diseases
Testing the safety of an IV stem cell treatment for lung diseases like COPD and asthma
📍 Medical Surgical Associates Center · St John's, · Get directions →
This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Pulmonary Diseases
- Depression
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
Testing how ketamine affects decision-making and emotions in depression
📍 Emory University · Atlanta, GA · Get directions →
The main purpose of this study is to investigate the effects of ketamine on decision-making and emotion processing in a sample of individuals diagnosed with Major Depressive Disorder (MDD).
- Depression
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET
Testing a PET brain scan tracer to image a brain enzyme in depression
📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →
Background: Major depressive disorder (MDD) is a psychiatric condition. People with MDD have occasional bouts of depressive symptoms; these bouts are called major depressive episodes (MDEs).
- Depression
Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains
Testing spinal sensory-to-brain pathways in people with depression
📍 Lindner Center of Hope · Mason, OH · Get directions →
Spinal interoceptive pathways (SIPs) convey bodily signals to an interoceptive system in the brain and their dysregulation is linked to major depressive disorder (MDD). Current treatments are partially effective and the role of SIPs in MDD is vastly unexplored.
- Fatty liver disease (NASH/MASH)💵 May compensate
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Testing miricorilant’s effect on liver fat in people with MASH
📍 University of Missouri · Columbia, MO · Get directions →
A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients with Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Depression
ENA-001 for Opioid Induced Respiratory Depression
Testing a new medicine’s safety and how it behaves in the body for opioid breathing problems
📍 South Florida Research Phase I-IV · Miami, FL · +2 more US sites · Get directions →
This study is a Phase I clinical trial to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles with single intravenous (IV) and intramuscular (IM) doses of ENA-001.